相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
Jeffrey S. Ross et al.
CLINICAL CANCER RESEARCH (2014)
Genome-wide association study identifies multiple loci associated with bladder cancer risk
Jonine D. Figueroa et al.
HUMAN MOLECULAR GENETICS (2014)
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic allterations and targets of therapy
Jeffrey S. Ross et al.
MODERN PATHOLOGY (2014)
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Gopa Iyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
Petros D. Grivas et al.
MOLECULAR MEDICINE (2013)
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Guangwu Guo et al.
NATURE GENETICS (2013)
Frequent truncating mutations of STAG2 in bladder cancer
David A. Solomon et al.
NATURE GENETICS (2013)
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
F. Petrelli et al.
ANNALS OF ONCOLOGY (2012)
EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells
Magdalena M. Grabowska et al.
CELLULAR SIGNALLING (2012)
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
Yu-Ning Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
CD10 and E-Cad Expression in Urinary Bladder Urothelial and Squamous Cell Carcinoma
Ola M. Omran
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2012)
Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection
Mototsugu Muramaki et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Immune expression of E-cadherin and α, β and γ-Catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas
Sabrina Thalita dos Reis et al.
INTERNATIONAL BRAZ J UROL (2012)
Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
Yuh-Shyan Tsai et al.
ADVANCES IN UROLOGY (2012)
Activation of EGFR Promotes Squamous Carcinoma SCC10A Cell Migration and Invasion Via Inducing EMT-Like Phenotype Change and MMP-9-Mediated Degradation of E-Cadherin
Jian-Hong Zuo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Noah M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
Daniel P. Petrylak et al.
BJU INTERNATIONAL (2010)
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier et al.
PLOS ONE (2010)
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
G. K. Philips et al.
ANNALS OF ONCOLOGY (2009)
A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
Christian Wuelfing et al.
CANCER (2009)
Sensitivity to epidermal growth factor receptor inhibitor requires E-cedherin expression in urothelial carcinoma cells
Peter C. Black et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
First-line single-agent cetuximab in patients with advanced colorectal cancer
A. Pessino et al.
ANNALS OF ONCOLOGY (2008)
The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma
Fikret Erdemir et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2007)
Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome
Christopher Kramer et al.
CANCER (2007)
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens - Evidence of schedule-dependent synergy
Lynsey A. McHugh et al.
UROLOGY (2007)
Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis
Mathias Munk et al.
BJU INTERNATIONAL (2007)
The prognostic value of E-cadherin, α-, β-, and γ-catenin in urothelial cancer of the upper urinary tract
K Kashibuchi et al.
EUROPEAN UROLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma
G Fromont et al.
EUROPEAN UROLOGY (2005)
The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients
Arisan Serdar et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy
K Matsumoto et al.
JOURNAL OF UROLOGY (2003)
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup
RA Byrne et al.
JOURNAL OF UROLOGY (2001)
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder
SF Shariat et al.
UROLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
